| Psoriasis vulgaris
Sotyktu vs Tazorac
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Sotyktu vs Tazorac with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTazorac has a higher rate of injection site reactions vs Sotyktu based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tazorac but not Sotyktu, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sotyktu
Tazorac
At A Glance
Oral
Daily
TYK2 inhibitor
Topical
Daily
Retinoid
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Acne Vulgaris
Dosing
Psoriasis vulgaris, Arthritis, Psoriatic 6 mg orally once daily, with or without food; do not crush, cut, or chew tablets; not recommended in severe hepatic impairment (Child-Pugh C).
Psoriasis vulgaris Apply a thin film (2 mg/cm2) of 0.05% cream once daily in the evening to psoriatic lesions only; increase to 0.1% if tolerated and medically indicated.
Acne Vulgaris Apply a thin layer (2 mg/cm2) of 0.1% cream once daily in the evening to affected facial skin areas after gentle cleansing and drying.
Contraindications
- History of hypersensitivity reaction to deucravacitinib or any excipient in SOTYKTU
- Pregnancy (retinoids may cause fetal harm)
- Known hypersensitivity to any component of TAZORAC Cream
Adverse Reactions
Most common (>=1%) Upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis, acne
Serious Pneumonia, COVID-19, malignancies including breast cancer, hepatocellular carcinoma, and lymphoma
Most common (>=10%) Psoriasis: pruritus, erythema, burning; Acne: desquamation, dry skin, erythema, burning sensation
Serious Embryofetal toxicity, photosensitivity and risk of sunburn
Postmarketing Blister, dermatitis, urticaria, skin exfoliation, skin discoloration (hyperpigmentation or hypopigmentation), swelling at or near application sites, pain
Pharmacology
TYK2 inhibitor; deucravacitinib binds the regulatory domain of TYK2, allosterically inhibiting receptor-mediated TYK2 activation and downstream STAT signaling via the JAK-STAT pathway.
Tazarotene is a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds retinoic acid receptors RAR-beta and RAR-gamma with relative selectivity and may modify gene expression in psoriatic and acne-affected skin.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sotyktu
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
No coverage data available for Tazorac.
UnitedHealthcare
Sotyktu
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
No coverage data available for Tazorac.
Humana
Sotyktu
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
No coverage data available for Tazorac.
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Psoriasis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Tazorac.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SotyktuView full Sotyktu profile
TazoracView full Tazorac profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.